Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

This study reported that finasteride 1 mg significantly improved hair growth in men aged 41 to 60 with predominantly vertex male pattern hair loss over 24 months compared to placebo.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

This study found no significant associations between the polymorphisms of SRD5A1 and SRD5A2 genes and androgenetic alopecia, clinical types of baldness, or response to finasteride in Koreans.

In this study, adults with persistent facial erythema of rosacea showed significantly greater improvement when treated with once-daily oxymetazoline cream compared to a vehicle, and using baseline photographs in assessments enhanced the accuracy by reducing perceived vehicle effects.

This study observed that 54% of men with male pattern hair loss showed hair growth improvement in the vertex region after 6 months of treatment with oral finasteride.

Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

This study found that combining minoxidil 0.1% and dutasteride 0.01% applied topically after microneedling was significantly more effective than using dutasteride alone with microneedling in improving female pattern hair loss in 40 female patients.

This study found that Rap1 deficiency in mice may lead to telomere shortening, DNA damage, and impaired mitochondrial function, contributing to cardiac aging and dysfunction.

In this study, men taking 1 mg/day of finasteride for 12 months showed minor metabolic changes and slight improvements in glucose metabolism.

This article reviews long-term data on the efficacy and safety of finasteride over five years but reports no new clinical results.

This report documents the first cases in Korea of painful bilateral gynecomastia associated with taking 1mg of oral finasteride (Propecia) for male androgenetic alopecia.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This commentary discusses the practice of prescribing and dividing Proscar tablets for cost-effective finasteride use and reports no new clinical findings.

This study found that long-term treatment with finasteride 1 mg/day significantly improved scalp hair growth and was well tolerated in men with androgenetic alopecia over five years compared to placebo.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

In this study, men using finasteride-1 mg long-term for androgenic alopecia were more likely to receive PDE5i prescriptions sooner than non-users, while also having reduced rates of elevated PSA and prostate cancer diagnoses.

This study found that both oral minoxidil and topical 5% minoxidil were effective and safe for treating female pattern hair loss over 24 weeks, with oral administration not being inferior to topical treatment.

This study found that in Taiwanese men with androgenetic alopecia, finasteride 1 mg/day over 1 year slowed hair loss and promoted hair growth, with minimal adverse effects.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

Photography is a simple and effective way to track hair loss treatment progress with finasteride.

This study found that a daily dose of 1 mg finasteride is effective for treating male pattern baldness, but benefits typically require at least three months to manifest and ongoing treatment is necessary to maintain results.

In this study, finasteride 1 mg demonstrated sustained efficacy over 10 years for men with androgenetic alopecia, especially in those over 30 or with higher AGA grades, with minimal side effects reported.